Testing two breast cancer drugs together for cancer that has spread to the brain
Original title: Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is an early test in people, done to find the right dose and see how the two drugs work together.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study is testing whether two drugs, elacestrant and abemaciclib, can help people whose breast cancer has spread to the brain.
Who this trial is for. This study is for women and men with breast cancer that has spread to the brain. The cancer must be the type that is estrogen receptor positive and HER2 negative. It tests the drug elacestrant given together with the drug abemaciclib.
Where it stands. This study has not reported results. The first part, called phase 1b, was set up to pick the dose to use in the next part. The phase 2 part is still going. Whether the two drugs together help people with brain metastases is not known yet.
What this means, and what it doesn't
What it could mean: Nothing here tells you if this drug pair works. It is still being tested. If your breast cancer is estrogen receptor positive and HER2 negative and it has spread to the brain, you could ask your care team whether a study like this makes sense for you.
What it doesn't mean: This does not mean the treatment works. A trial is a test, not a proven treatment. Joining a trial is not a guarantee that you will be helped. Some people in a trial do not benefit, and side effects are possible. This is not a cure, and no one can promise it will become one.
Source: ClinicalTrials.gov, August 6, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.